title: Haematological recovery in poor and good haematopoietic stem cell mobilisers.
abstract: OBJECTIVE
  Evaluate whether poor mobilisers had delayed haematopoietic (neutrophil and platelet) recovery despite receiving similar cell dose as good mobilisers.
  
  
  BACKGROUND
  Autologous haematopoietic progenitor cell (HPC) transplantation is indicated to treat some haematological malignancies. This procedure requires HPC mobilisation from bone marrow to peripheral blood. Cell dose is important for a fast haematological recovery. Despite being poor mobilisers, some patients can collect enough cell numbers for transplantation.
  
  
  RESULTS
  Fifteen poor mobiliser patients (peak of CD34+ cells ≤10 µL(-1) in peripheral blood) were transplanted at our institution. Haematological recovery (neutrophil ≥ 500 µL(-1) ) in this group was compared to that observed in the group of 16 patients of good mobilisers (peak of CD34+ cells ≥20 µL(-1) in peripheral blood) who received similar cell dose (2·637 ± 0·1744 × 10(6)  kg(-1) vs 2·727 ± 0·1746 × 10(6)  kg(-1) ; P = 0·7177). The poor mobiliser group had neutrophil and platelet recovery later than the good mobiliser group (on day 12, range 9-14 vs day 10, range 9-22, P = 0·0381 for neutrophil, and on day 22·89 ± 11·16 and 14·08 ± 4·821, P = 0·0193 for platelet). Mortality rates and transfusion requirements were not different between the groups.
  
  
  CONCLUSIONS
  Poor mobilisers have delayed neutrophil and platelet recovery after autologous HPC transplantation despite having received the same cell dose as good mobilisers.
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. gil@hemocentro.fmrp.usp.br.
authors.forename: G C
authors.initials: GC
authors.lastname: De Santis
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: A C
authors.initials: AC
authors.lastname: Garcia-Silva
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: N C G
authors.initials: NC
authors.lastname: Chiaramonte
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: M D
authors.initials: MD
authors.lastname: Orellana
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: B P A
authors.initials: BP
authors.lastname: Prado
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: L C
authors.initials: LC
authors.lastname: Oliveira
authors.affiliation: Haematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: B P
authors.initials: BP
authors.lastname: Simões
authors.affiliation: Center for Cell-Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.|Haematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
authors.forename: D T
authors.initials: DT
authors.lastname: Covas
mesh_terms: D000328:Adult; D000368:Aged; D064592:Autografts; D018572:Disease-Free Survival; D005260:Female; D019337:Hematologic Neoplasms / Q000097:blood / Q000401:mortality* / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
keywords: haematopoietic progenitor cell; mobilisation; transplantation